Piperazine Abuse and Psychosis: A Systematic Review of the Literature
Abstract
:1. Introduction
2. Materials and Methods
2.1. Systematic Review Procedures
2.2. Data Synthesis Strategy
3. Results
Name, Year | Substance | Study Design | Population (N, M, F) | MA ± Standard Deviation | Psychiatric Comorbidity | Medical Comorbidity (Yes/No) | Administration | Poly-Abuse (Substance) | Non-Psychotic Psychiatric Symptoms | Thought and Ideation Disturbances | Hallucinations | Psychedelic Experience (Yes/No) | Outcome |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Austin and Monasterio et al., 2004 [44] | “Rapture” (BZP) in addition to small quantities of cannabis and nitrous oxid | Case report | M = 1 | 20 | No | NA | Oral | Cannabis, nitrous oxide | Anxiety | Persecution delusions, poisonous delirium | Auditory, visual, and olfactory hallucinations | Yes | Acute psychosis with remission |
Bossong et al., 2010 [43] | mCPP | Observational study | N = 79 | NA | NA | NA | Oral | NA | Anxiety, dizziness, agitation | Unspecified delusion, paranoia | Unspecified hallucinations | NA | NA |
Thompson et al., 2010 [45] | BZP, TFMPP | Randomized, double-blind, placebo-controlled trial | N = 35 (M = 22 F = 13) | MA = 24 | No | No | Oral | Alcohol, benzodiazepines | Anxiety, agitation, insomnia | Present but unspecified | Unspecified hallucinations | Yes | Acute psychosis with remission |
Wilkins et al., 2008 [42] | BZP and TFMPP | Observational study | NA | NA | NA | NA | NA | NA | Mood swings, insomnia, poor appetite, hot/cold flushes, heavy sweating, confusion, irritability, feelings of aggression, suicidal thoughts | Paranoia | Auditory and visual hallucinations | Yes | NA |
4. Discussion
Study Limitations
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Schifano, F.; Orsolini, L.; Duccio Papanti, G.; Corkery, J.M. Novel psychoactive substances of interest for psychiatry. World Psychiatry 2015, 14, 15–26. [Google Scholar] [CrossRef] [PubMed]
- Fitzgerald, N.D.; Cottler, L.B.; Palamar, J.J. Public health surveillance of new psychoactive substances: Recent developments. Curr. Opin. Psychiatry 2024, 37, 270–276. [Google Scholar] [CrossRef] [PubMed]
- European Monitoring Centre for Drugs and Drug Addiction. EMCDDA Operating Guidelines for the European Union Early Warning System on New Psychoactive Substances; Publications Office of the European Union: Luxembourg, 2019; ISBN 978-92-9497-460-0. [Google Scholar] [CrossRef]
- Baumeister, D.; Tojo, L.M.; Tracy, D.K. Legal highs: Staying on top of the flood of novel psychoactive substances. Ther. Adv. Psychopharmacol. 2015, 5, 97–132. [Google Scholar] [CrossRef] [PubMed]
- Das, S.; Chatterjee, S.S.; Mitra, S. “A tale of tail”: A case of lizard tail abuse. Indian J. Psychiatry 2020, 62, 454–455. [Google Scholar] [CrossRef]
- Jadav, D.; Shedge, R.; Meshram, V.P.; Kanchan, T.; Shekhawat, R.S. Snake venom—An unconventional recreational substance for psychonauts in India. J. Forensic Leg. Med. 2022, 91, 102398. [Google Scholar] [CrossRef]
- United Nations: Office on Drugs and Crime [Internet]. UNODC Annual Report. Available online: https://www.unodc.org/unodc/en/about-unodc/annual-report.html (accessed on 25 August 2024).
- Treatment (US) C for SA. Drug Cultures and the Culture of Recovery. In Improving Cultural Competence; [Internet]; Substance Abuse and Mental Health Services Administration (US): Rockville, MD, USA, 2014. Available online: https://www.ncbi.nlm.nih.gov/books/NBK248421/ (accessed on 25 August 2024).
- Davey, Z.; Schifano, F.; Corazza, O.; Deluca, P.; on behalf of the Psychonaut Web Mapping Group. e-Psychonauts: Conducting research in online drug forum communities. J. Ment. Health 2012, 21, 386–394. [Google Scholar] [CrossRef]
- Martinotti, G.; De Risio, L.; Vannini, C.; Schifano, F.; Pettorruso, M.; Di Giannantonio, M. Substance-related exogenous psychosis: A postmodern syndrome. CNS Spectr. 2021, 26, 84–91. [Google Scholar] [CrossRef]
- Whitley, R. Postmodernity and Mental Health. Harv. Rev. Psychiatry 2008, 16, 352–364. [Google Scholar] [CrossRef]
- Pichini, S.; Di Trana, A.; Torrens, M.; Scherbaum, N.; Zaami, S. Editorial: New Trends of Substance Abuse: Looking for New Psychotropic Effects of Chem Sex Drugs, Cognitive Enhancers, and New Psychoactive Substances. Front. Psychiatry 2020, 11, 612192. [Google Scholar] [CrossRef]
- Schuler, M.S.; Ramchand, R. Examining Inhalant Use Among Sexual Minority Adults in a National Sample: Drug-Specific Risks or Generalized Risk? LGBT Health 2023, 10, 80–85. [Google Scholar] [CrossRef]
- di Giannantonio, M.; Negri, A.; Schiavone, S.; Vannini, C.; Pettorruso, M.; De-Giorgio, F.; Verrastro, V.; Trabace, L.; Corbo, M.; Gottardo, R.; et al. Prescription Drug Misuse in “Clubbers” and Disco Goers in Ibiza. Front. Psychiatry 2020, 11, 592594. [Google Scholar] [CrossRef] [PubMed]
- Chakraborty, K.; Neogi, R.; Basu, D. Club drugs: Review of the ‘rave’ with a note of concern for the Indian scenario. Indian J. Med. Res. 2011, 133, 594–604. [Google Scholar] [PubMed]
- Schifano, F.; Chiappini, S.; Corkery, J.M.; Scherbaum, N.; Guirguis, A. The e-psychonaut drugs’ psychopharmacology. Curr. Opin. Pharmacol. 2021, 57, 165–174. [Google Scholar] [CrossRef] [PubMed]
- Orsolini, L.; St John-Smith, P.; McQueen, D.; Papanti, D.; Corkery, J.; Schifano, F. Evolutionary Considerations on the Emerging Subculture of the E-psychonauts and the Novel Psychoactive Substances: A Comeback to the Shamanism? Curr. Neuropharmacol. 2017, 15, 731–737. [Google Scholar] [CrossRef] [PubMed]
- Zaami, S.; Marinelli, E.; Varì, M.R. New Trends of Substance Abuse During COVID-19 Pandemic: An International Perspective. Front. Psychiatry 2020, 11, 700. [Google Scholar] [CrossRef]
- Catalani, V.; Arillotta, D.; Corkery, J.M.; Guirguis, A.; Vento, A.; Schifano, F. Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach. Front. Psychiatry 2020, 11, 632405. [Google Scholar] [CrossRef]
- Schifano, F.; Chiappini, S.; Corkery, J.; Guirguis, A. Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. Brain Sci. 2018, 8, 73. [Google Scholar] [CrossRef]
- Miliano, C.; Margiani, G.; Fattore, L.; De Luca, M. Sales and Advertising Channels of New Psychoactive Substances (NPS): Internet, Social Networks, and Smartphone Apps. Brain Sci. 2018, 8, 123. [Google Scholar] [CrossRef]
- Schifano, F.; Leoni, M.; Martinotti, G.; Rawaf, S.; Rovetto, F. Importance of Cyberspace for the Assessment of the Drug Abuse Market: Preliminary Results from the Psychonaut 2002 Project. Cyberpsychol. Behav. 2003, 6, 405–410. [Google Scholar] [CrossRef]
- European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2024: Trends and Developments; [Internet]; LU: Publications Office: Luxembourg, 2024; Available online: https://data.europa.eu/doi/10.2810/161905 (accessed on 14 June 2024).
- Chiappini, S.; Schifano, F. What about “Pharming”? Issues Regarding the Misuse of Prescription and Over-the-Counter Drugs. Brain Sci. 2020, 10, 736. [Google Scholar] [CrossRef]
- Schifano, F.; Chiappini, S.; Miuli, A.; Mosca, A.; Santovito, M.C.; Corkery, J.M.; Guirguis, A.; Pettorruso, M.; Di Giannantonio, M.; Martinotti, G. Focus on Over-the-Counter Drugs’ Misuse: A Systematic Review on Antihistamines, Cough Medicines, and Decongestants. Front. Psychiatry 2021, 12, 657397. [Google Scholar] [CrossRef] [PubMed]
- Schifano, F.; Napoletano, F.; Chiappini, S.; Guirguis, A.; Corkery, J.M.; Bonaccorso, S.; Ricciardi, A.; Scherbaum, N.; Vento, A. New/emerging psychoactive substances and associated psychopathological consequences. Psychol. Med. 2021, 51, 30–42. [Google Scholar] [CrossRef] [PubMed]
- Rinaldi, R.; Bersani, G.; Marinelli, E.; Zaami, S. The rise of new psychoactive substances and psychiatric implications: A wide-ranging, multifaceted challenge that needs far-reaching common legislative strategies. Hum. Psychopharmacol. Clin. Exp. 2020, 35, e2727. [Google Scholar] [CrossRef]
- Chiappini, S.; Mosca, A.; Miuli, A.; Santovito, M.C.; Orsolini, L.; Corkery, J.M.; Guirguis, A.; Pettorruso, M.; Martinotti, G.; Di Giannantonio, M.; et al. New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature. Medicina 2021, 57, 580. [Google Scholar] [CrossRef]
- Hasin, D.S.; O’Brien, C.P.; Auriacombe, M.; Borges, G.; Bucholz, K.; Budney, A.; Compton, W.M.; Crowley, T.; Ling, W.; Petry, N.M.; et al. DSM-5 Criteria for Substance Use Disorders: Recommendations and Rationale. Am. J. Psychiatry 2013, 170, 834–851. [Google Scholar] [CrossRef] [PubMed]
- Webb, L.; Shi, X.; Goodair, C.; Cheeta, S. Trends in Mortality from Novel Psychoactive Substances as “Legal Highs”: Gender Differences in Manner of Death and Implications for Risk Differences for Women. Front. Psychiatry 2022, 13, 890840. [Google Scholar] [CrossRef]
- Schifano, F.; Orsolini, L.; Papanti, D.; Corkery, J. NPS: Medical Consequences Associated with Their Intake. In Neuropharmacology of New Psychoactive Substances (NPS); [Internet]; Current Topics in Behavioral Neurosciences; Baumann, M.H., Glennon, R.A., Wiley, J.L., Eds.; Springer International Publishing: Cham, Switzerland, 2016; Volume 32, pp. 351–380. Available online: https://link.springer.com/10.1007/7854_2016_15 (accessed on 14 June 2024).
- Fiorentini, A.; Sara Volonteri, L.; Dragogna, F.; Rovera, C.; Maffini, M.; Carlo Mauri, M.; Altamura, C.A. Substance-Induced Psychoses: A Critical Review of the Literature. Curr. Drug Abus. Rev. 2011, 4, 228–240. [Google Scholar] [CrossRef]
- Papanti, D.; Schifano, F.; Botteon, G.; Bertossi, F.; Mannix, J.; Vidoni, D.; Impagnatiello, M.; Pascolo-Fabrici, E.; Bonavigo, T. “Spiceophrenia”: A systematic overview of “Spice”-related psychopathological issues and a case report. Hum. Psychopharmacol. Clin. Exp. 2013, 28, 379–389. [Google Scholar] [CrossRef]
- Gee, P.; Schep, L.J. Chapter12-1-Benzylpiperazine and other piperazine-based stimulants. In Novel Psychoactive Substances, 2nd ed.; [Internet]; Dargan, P., Wood, D., Eds.; Academic Press: Boston, MA, USA, 2022; pp. 301–332. Available online: https://www.sciencedirect.com/science/article/pii/B9780128187883000097 (accessed on 25 August 2024).
- Cavier, R. Anthelmintic properties of piperazine and its derivatives. Ann. Pharm. Fr. 1955, 13, 539–556. [Google Scholar]
- De Boer, D.; Bosman, I.J.; Hidvégi, E.; Manzoni, C.; Benkö, A.A.; Dos Reys, L.J.A.L.; Maes, R.A.A. Piperazine-like compounds: A new group of designer drugs-of-abuse on the European market. Forensic Sci. Int. 2001, 121, 47–56. [Google Scholar] [CrossRef]
- Arbo, M.D.; Bastos, M.L.; Carmo, H.F. Piperazine compounds as drugs of abuse. Drug Alcohol Depend. 2012, 122, 174–185. [Google Scholar] [CrossRef] [PubMed]
- Welz, A.; Koba, M. Piperazine derivatives as dangerous abused compounds. Acta Pharm. 2020, 70, 423–441. [Google Scholar] [CrossRef] [PubMed]
- PRISMA-P Group; Moher, D.; Shamseer, L.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev. 2015, 4, 1. [Google Scholar] [CrossRef] [PubMed]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef]
- Bernardo, W.M. PRISMA statement and PROSPERO. Int. Braz J Urol Off. J. Braz. Soc. Urol. 2017, 43, 383–384. [Google Scholar] [CrossRef]
- Wilkins, C.; Sweetsur, P.; Girling, M. Patterns of benzylpiperazine/trifluoromethylphenylpiperazine party pill use and adverse effects in a population sample in New Zealand. Drug Alcohol Rev. 2008, 27, 633–639. [Google Scholar] [CrossRef]
- Bossong, M.; Brunt, T.; Van Dijk, J.; Rigter, S.; Hoek, J.; Goldschmidt, H.; Niesink, R. mCPP: An undesired addition to the ecstasy market. J. Psychopharmacol. 2010, 24, 1395–1401. [Google Scholar] [CrossRef]
- Austin, H.; Monasterio, E. Acute Psychosis Following Ingestion of ‘Rapture’. Australas. Psychiatry 2004, 12, 406–408. [Google Scholar] [CrossRef]
- Thompson, I.; Williams, G.; Caldwell, B.; Aldington, S.; Dickson, S.; Lucas, N.; McDowall, J.; Weatherall, M.; Robinson, G.; Beasley, R. Randomised double-blind, placebo-controlled trial of the effects of the ‘party pills’ BZP/TFMPP alone and in combination with alcohol. J. Psychopharmacol. 2010, 24, 1299–1308. [Google Scholar] [CrossRef]
- Staack, R.F. Piperazine designer drugs of abuse. Lancet 2007, 369, 1411–1413. [Google Scholar] [CrossRef]
- Chiang, M.; Lombardi, D.; Du, J.; Makrum, U.; Sitthichai, R.; Harrington, A.; Shukair, N.; Zhao, M.; Fan, X. Methamphetamine-associated psychosis: Clinical presentation, biological basis, and treatment options. Hum. Psychopharmacol. Clin. Exp. 2019, 34, e2710. [Google Scholar] [CrossRef] [PubMed]
- Grant, K.M.; LeVan, T.D.; Wells, S.M.; Li, M.; Stoltenberg, S.F.; Gendelman, H.E.; Carlo, G.; Bevins, R.A. Methamphetamine-associated psychosis. J. Neuroimmune Pharmacol. Off. J. Soc. NeuroImmune Pharmacol. 2012, 7, 113–139. [Google Scholar] [CrossRef]
- Orsolini, L.; Chiappini, S.; Corkery, J.M.; Guirguis, A.; Papanti, D.; Schifano, F. The use of new psychoactive substances (NPS) in young people and their role in mental health care: A systematic review. Expert Rev. Neurother. 2019, 19, 1253–1264. [Google Scholar] [CrossRef] [PubMed]
- Martinotti, G.; Chiappini, S.; Mosca, A.; Miuli, A.; Santovito, M.C.; Pettorruso, M.; Skryabin, V.; Sensi, S.L.; Giannantonio, M.D. Atypical Antipsychotic Drugs in Dual Disorders: Current Evidence for Clinical Practice. Curr. Pharm. Des. 2022, 28, 2241–2259. [Google Scholar] [CrossRef]
- Chiappini, S.; Mosca, A.; Miuli, A.; Di Carlo, F.; d’Andrea, G.; Napolitano, A.; Santangelo, M.; Esposito, C.; Rosazza, A.; Haefele, E.; et al. Aripiprazole once monthly as a maintenance treatment for patients with schizophrenia and alcohol/substance use disorder: An observational, real-world study. Adv. Dual Diagn. 2023, 16, 185–198. [Google Scholar] [CrossRef]
- Chiappini, S.; Cavallotto, C.; Mosca, A.; Di Carlo, F.; Piro, T.; Giovannetti, G.; Pasino, A.; Vicinelli, M.; Lorenzini, C.; Di Paolo, M.; et al. Investigating the Effectiveness of Brexpiprazole in Subjects with Schizophrenia Spectrum Illness and Co-Occurring Substance Use Disorder: A Prospective, Multicentric, Real-World Study. Pharmaceuticals 2024, 17, 535. [Google Scholar] [CrossRef]
- Cavallotto, C.; Chiappini, S.; Mosca, A.; d’Andrea, G.; Di Carlo, F.; Piro, T.; Susini, O.; Stefanelli, G.; Di Cesare, A.; Ricci, V.; et al. Examining Lurasidone Efficacy in Patients with Schizophrenia Spectrum Illness and Concurrent Alcohol and Substance Use Disorder: A Prospective, Multicentric, Real-World Investigation. J. Clin. Med. 2024, 13, 2206. [Google Scholar] [CrossRef] [PubMed]
- Baldaçara, L.; Ramos, A.; Castaldelli-Maia, J.M. Managing drug-induced psychosis. Int. Rev. Psychiatry 2023, 35, 496–502. [Google Scholar] [CrossRef]
- Abdel-Baki, A.; Thibault, D.; Medrano, S.; Stip, E.; Ladouceur, M.; Tahir, R.; Potvin, S. Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder. Early Interv. Psychiatry 2020, 14, 69–79. [Google Scholar] [CrossRef]
- Green, A.I.; Tohen, M.F.; Hamer, R.M.; Strakowski, S.M.; Lieberman, J.A.; Glick, I.; Scott Clark, W. First episode schizophrenia-related psychosis and substance use disorders: Acute response to olanzapine and haloperidol. Schizophr. Res. 2004, 66, 125–135. [Google Scholar] [CrossRef]
- Simonato, P.; Corazza, O.; Santonastaso, P.; Corkery, J.; Deluca, P.; Davey, Z.; Blaszko, U.; Schifano, F. Novel psychoactive substances as a novel challenge for health professionals: Results from an Italian survey. Hum. Psychopharmacol. Clin. Exp. 2013, 28, 324–331. [Google Scholar] [CrossRef]
- Orsolini, L.; Chiappini, S.; Papanti, D.; De Berardis, D.; Corkery, J.M.; Schifano, F. The Bridge Between Classical and “Synthetic”/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective. Front. Psychiatry 2019, 10, 851. [Google Scholar] [CrossRef] [PubMed]
- Neicun, J.; Steenhuizen, M.; Van Kessel, R.; Yang, J.C.; Negri, A.; Czabanowska, K.; Corazza, O.; Roman-Urrestarazu, A. Mapping novel psychoactive substances policy in the EU: The case of Portugal, the Netherlands, Czech Republic, Poland, the United Kingdom and Sweden. PLoS ONE 2019, 14, e0218011. [Google Scholar] [CrossRef] [PubMed]
- Santos-Toscano, R.; Guirguis, A.; Davidson, C. How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe. Br. J. Clin. Pharmacol. 2020, 86, 452–481. [Google Scholar] [CrossRef]
- Nutt, D. New psychoactive substances: Pharmacology influencing UK practice, policy and the law. Br. J. Clin. Pharmacol. 2020, 86, 445–451. [Google Scholar] [CrossRef]
- Vicknasingam, B.; Narayanan, S.; Singh, D.; Corazza, O. Global strategy for New Psychoactive Substances: An update. Curr. Opin. Psychiatry 2020, 33, 295–300. Available online: https://pubmed.ncbi.nlm.nih.gov/32398543/ (accessed on 2 September 2024). [CrossRef]
- Wood, D.M.; Dargan, P.I. The challenge of the novel psychoactive substances: How have we responded and what are the implications of this response? Br. J. Clin. Pharmacol. 2020, 86, 407–409. [Google Scholar] [CrossRef] [PubMed]
- Jones, J.L. Perspectives on the therapeutic potential of MDMA: A nation-wide exploratory survey among substance users. Front. Psychiatry 2023, 14, 1096298. [Google Scholar] [CrossRef]
- Australia to Allow MDMA-Assisted Therapy for PTSD-Alcohol and Drug Foundation [Internet]. Available online: https://adf.org.au/insights/mdma-ptsd/ (accessed on 25 August 2024).
- Mosca, A.; Chiappini, S.; Miuli, A.; Mancusi, G.; Santovito, M.C.; Di Carlo, F.; Pettorruso, M.; Corkery, J.M.; Canessa, C.; Martinotti, G.; et al. Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature. Curr. Neuropharmacol. 2023, 21, 2178–2194. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mosca, A.; Chiappini, S.; Miuli, A.; Mancusi, G.; Cavallotto, C.; Corkery, J.M.; Miotti, L.; Pettorruso, M.; Martinotti, G.; Schifano, F. Piperazine Abuse and Psychosis: A Systematic Review of the Literature. Psychiatry Int. 2024, 5, 552-563. https://doi.org/10.3390/psychiatryint5030040
Mosca A, Chiappini S, Miuli A, Mancusi G, Cavallotto C, Corkery JM, Miotti L, Pettorruso M, Martinotti G, Schifano F. Piperazine Abuse and Psychosis: A Systematic Review of the Literature. Psychiatry International. 2024; 5(3):552-563. https://doi.org/10.3390/psychiatryint5030040
Chicago/Turabian StyleMosca, Alessio, Stefania Chiappini, Andrea Miuli, Gianluca Mancusi, Clara Cavallotto, John M. Corkery, Livia Miotti, Mauro Pettorruso, Giovanni Martinotti, and Fabrizio Schifano. 2024. "Piperazine Abuse and Psychosis: A Systematic Review of the Literature" Psychiatry International 5, no. 3: 552-563. https://doi.org/10.3390/psychiatryint5030040
APA StyleMosca, A., Chiappini, S., Miuli, A., Mancusi, G., Cavallotto, C., Corkery, J. M., Miotti, L., Pettorruso, M., Martinotti, G., & Schifano, F. (2024). Piperazine Abuse and Psychosis: A Systematic Review of the Literature. Psychiatry International, 5(3), 552-563. https://doi.org/10.3390/psychiatryint5030040